RxDoctor Payments Data

Jonathan Cosin, MD

Gynecologic Oncology · New Britain, CTNPI 1417936139

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.9%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 70.5% of it on its own, with 1 other manufacturer making up the rest. 2023 is the largest year on record at $549, 2.2 times the $246 reported in 2020.

$834in general payments, 2019–2025

Across 9 payments — averaging $92.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$588
  • Covidien LP$246
$84,432in research payments, 2019–2025

Across 32 payments — averaging $2638.51 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AstraZeneca$46K
  • Covidien LP$20K
  • Medtronic$19K

What the payments were for

  • Consulting fees$50060%
  • Travel & lodging$24630%
  • Food & beverage$8811%

General payments by program year

20
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Medtronic5$588
Covidien LP4$246

How this compares

$834 in reported general payments places this provider in the 55th percentile of 25 gynecologic oncology providers in Connecticut.

See all gynecologic oncology providers in Connecticut

Medicare billing

Part B allowed, 2024
$19,331
Medicare patients
34
Services billed
92

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in New Britain

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →